Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

3.3050

+0.0750

(+2.32%)

As of 03:09PM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	3.2300
Open	3.2900
Bid	3.3100 x 2200
Ask	3.3200 x 800
Day's Range	3.2150 - 3.3650
52 Week Range	2.5000 - 6.7900
Volume	2,111,223
Avg. Volume	4,235,630

Market Cap	848.826M
Beta (5Y Monthly)	1.13
PE Ratio (TTM)	183.61
EPS (TTM)	0.0180
Earnings Date	Nov 09, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	9.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGEN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Agenus Inc.
Daily – Vickers Top Buyers & Sellers for 12/07/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
yesterdayArgus Research

All

News

Press Releases

Research Reports

Motley Fool
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.
Motley Fool
2 Falling-Knife Stocks Actually Worth Buying Right Now
November has been brutal for biotech stocks. Agenus' shares have been on a downward spiral ever since the FDA requested the company withdraw its BLA for the checkpoint inhibitor balstilimab last month.
GlobeNewswire
Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and Chief Executive Officer of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat hosted by Evercore on Tuesday, November 30th, 2021 at 1:50 PM EST. Registration can be